Millipore Sigma Vibrant Logo

324380 Doxorubicin, Hydrochloride - CAS 25316-40-9 - Calbiochem

View Products on Sigmaaldrich.com
324380
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited Availability
Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      CAS #Empirical Formula
      25316-40-9C₂₇H₂₉NO₁₁ · HCl
      Description
      OverviewAntitumor antibiotic and a highly effective myotoxin that inhibits topoisomerase II (IC50 = 100 nM). Binds to nucleic acids, presumably by specific intercalation into the DNA double helix, thereby inhibiting nucleic acid synthesis. Induces apoptosis in rhabdomyosarcoma cell lines. Also available as a 10 mM solution in H2O (Cat. No. 504042).
      Catalogue Number324380
      Brand Family Calbiochem®
      SynonymsAdriamycin, 14-Hydroxydaunomycin, HCl
      References
      ReferencesA'Hern, R.P., and Gore, M.E. 1995. J. Clin. Oncol. 13, 726.
      Nooter, K., et al. 1995. Br. J. Cancer 71, 556.
      Noviello, E., et al. 1994. Mutat. Res. 311, 21.
      Anderson, R.D., et al. 1993. Mutat. Res. 294, 215.
      Hershko, C., et al. 1993. J. Lab. Clin. Med. 122, 245.
      Jongmans, W., et al. 1993. Mutat. Res. 294, 207.
      O'Shaughnessy, J.A., and Cowan, K.H. 1993. J. Am. Med. Assoc. 270, 2089.
      Theyer, G., et al. 1993. J. Urol. 150, 1544.
      Tritton, T.R., and Yee, G. 1982. Science 217, 248.
      Product Information
      CAS number25316-40-9
      ATP CompetitiveN
      FormOrange to red powder
      Hill FormulaC₂₇H₂₉NO₁₁ · HCl
      Chemical formulaC₂₇H₂₉NO₁₁ · HCl
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targettopoisomerase 2
      Primary Target IC<sub>50</sub>100 nM
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSQI9295900
      Safety Information
      R PhraseR: 45-46

      May cause cancer.
      May cause heritable genetic damage.
      S PhraseS: 36/37-45-53-22-28

      Wear suitable protective clothing and gloves.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Avoid exposure - obtain special instructions before use.
      Do not breathe dust.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Carcinogenic / Teratogenic
      Storage +15°C to +30°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, refrigerate (4°C). Stock solutions are stable for up to 1 month at 4°C. Under acidic conditions doxorubicin is converted to a water-insoluble adriamycinone and a water soluble reducing sugar, daunosamine.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      324380 0

      Documentation

      Doxorubicin, Hydrochloride - CAS 25316-40-9 - Calbiochem MSDS

      Title

      Safety Data Sheet (SDS) 

      Doxorubicin, Hydrochloride - CAS 25316-40-9 - Calbiochem Certificates of Analysis

      TitleLot Number
      324380

      References

      Reference overview
      A'Hern, R.P., and Gore, M.E. 1995. J. Clin. Oncol. 13, 726.
      Nooter, K., et al. 1995. Br. J. Cancer 71, 556.
      Noviello, E., et al. 1994. Mutat. Res. 311, 21.
      Anderson, R.D., et al. 1993. Mutat. Res. 294, 215.
      Hershko, C., et al. 1993. J. Lab. Clin. Med. 122, 245.
      Jongmans, W., et al. 1993. Mutat. Res. 294, 207.
      O'Shaughnessy, J.A., and Cowan, K.H. 1993. J. Am. Med. Assoc. 270, 2089.
      Theyer, G., et al. 1993. J. Urol. 150, 1544.
      Tritton, T.R., and Yee, G. 1982. Science 217, 248.

      Brochure

      Title
      Tools and Tips for Analyzing Apoptosis
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision22-May-2018 JSW
      SynonymsAdriamycin, 14-Hydroxydaunomycin, HCl
      DescriptionAn anti-tumor antibiotic and a highly effective myotoxin that inhibits topoisomerase II (IC50 = 100 nM). Binds to nucleic acids, presumably by specific intercalation into the DNA double helix, inhibiting nucleic acid synthesis. Cytotoxicity seems to be due to its ability to intercalate with DNA, interact with plasma membranes, and take part in oxidation-reduction reactions. Induces apoptosis in rhabdomyosarcoma cell lines.
      FormOrange to red powder
      CAS number25316-40-9
      RTECSQI9295900
      Chemical formulaC₂₇H₂₉NO₁₁ · HCl
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityH₂O (10 mg/ml)
      Storage Protect from light
      +15°C to +30°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, refrigerate (4°C). Stock solutions are stable for up to 1 month at 4°C. Under acidic conditions doxorubicin is converted to a water-insoluble adriamycinone and a water soluble reducing sugar, daunosamine.
      Toxicity Carcinogenic / Teratogenic
      Merck USA index14, 3439
      ReferencesA'Hern, R.P., and Gore, M.E. 1995. J. Clin. Oncol. 13, 726.
      Nooter, K., et al. 1995. Br. J. Cancer 71, 556.
      Noviello, E., et al. 1994. Mutat. Res. 311, 21.
      Anderson, R.D., et al. 1993. Mutat. Res. 294, 215.
      Hershko, C., et al. 1993. J. Lab. Clin. Med. 122, 245.
      Jongmans, W., et al. 1993. Mutat. Res. 294, 207.
      O'Shaughnessy, J.A., and Cowan, K.H. 1993. J. Am. Med. Assoc. 270, 2089.
      Theyer, G., et al. 1993. J. Urol. 150, 1544.
      Tritton, T.R., and Yee, G. 1982. Science 217, 248.